文献速递认知障碍与痴呆

甘特珠单抗或索拉珠单抗在显性遗传性阿尔茨海默病中的下游生物标志物效应:DIAN-TU-001随机临床试验

Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2024-01-01

该研究分析了DIAN-TU-001随机双盲安慰剂对照试验中142例显性遗传性阿尔茨海默病基因变异携带者的脑脊液和血浆生物标志物纵向变化。与安慰剂相比,甘特珠单抗显著降低第4年脑脊液神经颗粒素水平,降低第1、2、4年血浆GFAP水平,并升高第2、4年脑脊液sTREM2水平;索拉珠单抗显著升高第4年脑脊液NfL(对数)水平。

要点

  • 甘特珠单抗较安慰剂降低第4年脑脊液神经颗粒素水平(β=-242.43 pg/mL,P<.001)。
  • 甘特珠单抗较安慰剂降低第1、2、4年血浆GFAP水平。
  • 索拉珠单抗较安慰剂升高第4年脑脊液NfL(对数)水平(β=0.14,P=.02)。

核心结论

  • 该随机临床试验支持纤维状淀粉样蛋白减少在显性遗传性阿尔茨海默病脑脊液和血浆中多种AD相关神经炎症和神经变性过程中的重要性。
  • 需要对散发性AD和DIAD进行抗聚集淀粉样蛋白治疗的额外研究,以确定非淀粉样蛋白生物标志物在判定疾病修饰中的效用。

研究设计与样本

  • DIAN-TU-001是一项双盲、安慰剂对照、随机临床试验,2012年至2019年在7个国家的25个研究中心开展,研究甘特珠单抗和索拉珠单抗在显性遗传性阿尔茨海默病(DIAD)中的作用。
  • 基因变异携带者按3:1随机分配至药物或安慰剂;本分析分析甘特珠单抗组、索拉珠单抗组和安慰剂组携带者的生物体液和神经影像。
  • 共筛查236例合格参与者,排除43例;最终纳入142例参与者(平均[SD]年龄44[10]岁;女性72例[51%]),其中甘特珠单抗组52例(37%)、索拉珠单抗组50例(35%)、安慰剂组40例(28%)。
  • 本分析于2023年4月至6月进行。

主要发现

  • 与安慰剂相比,甘特珠单抗显著降低第4年脑脊液神经颗粒素水平(平均[SD] β=-242.43[48.04] pg/mL;P<.001)。
  • 与安慰剂相比,甘特珠单抗显著降低血浆GFAP水平:第1年(平均[SD] β=-0.02[0.01] ng/mL;P=.02)、第2年(平均[SD] β=-0.03[0.01] ng/mL;P=.002)和第4年(平均[SD] β=-0.06[0.02] ng/mL;P<.001)。
  • 与安慰剂相比,甘特珠单抗显著升高第2年(平均[SD] β=1.12[0.43] ng/mL;P=.01)和第4年(平均[SD] β=1.06[0.52] ng/mL;P=.04)脑脊液sTREM2水平。
  • 与安慰剂相比,索拉珠单抗显著升高第4年脑脊液NfL(对数)水平(平均[SD] β=0.14[0.06];P=.02)。
  • 变化率的相关性分析发现,索拉珠单抗组和安慰剂组的脑脊液标志物及体液标志物与匹兹堡复合物B正电子发射断层扫描之间的相关性更强。

关键数值与推荐

  • 甘特珠单抗初始剂量为225 mg皮下注射每4周一次,2016年起每8周增加剂量直至1200 mg。
  • 索拉珠单抗初始剂量为400 mg静脉注射每4周一次,2017年起增加至每4周1600 mg。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Effects of antiamyloid agents, targeting either fibrillar or soluble monomeric amyloid peptides, on downstream biomarkers in cerebrospinal fluid (CSF) and plasma are largely unknown in dominantly inherited Alzheimer disease (DIAD). OBJECTIVE: To investigate longitudinal biomarker changes of synaptic dysfunction, neuroinflammation, and neurodegeneration in individuals with DIAD who are receiving antiamyloid treatment. DESIGN, SETTING, AND PARTICIPANTS: From 2012 to 2019, the Dominantly Inherited Alzheimer Network Trial Unit (DIAN-TU-001) study, a double-blind, placebo-controlled, randomized clinical trial, investigated gantenerumab and solanezumab in DIAD. Carriers of gene variants were assigned 3:1 to either drug or placebo. The present analysis was conducted from April to June 2023. DIAN-TU-001 spans 25 study sites in 7 countries. Biofluids and neuroimaging from carriers of DIAD gene variants in the gantenerumab, solanezumab, and placebo groups were analyzed. INTERVENTIONS: In 2016, initial dosing of gantenerumab, 225 mg (subcutaneously every 4 weeks) was increased every 8 weeks up to 1200 mg. In 2017, initial dosing of solanezumab, 400 mg (intravenously every 4 weeks) was increased up to 1600 mg every 4 weeks. MAIN OUTCOMES AND MEASURES: Longitudinal changes in CSF levels of neurogranin, soluble triggering receptor expressed on myeloid cells 2 (sTREM2), chitinase 3-like 1 protein (YKL-40), glial fibrillary acidic protein (GFAP), neurofilament light protein (NfL), and plasma levels of GFAP and NfL. RESULTS: Of 236 eligible participants screened, 43 were excluded. A total of 142 participants (mean [SD] age, 44 [10] years; 72 female [51%]) were included in the study (gantenerumab, 52 [37%]; solanezumab, 50 [35%]; placebo, 40 [28%]). Relative to placebo, gantenerumab significantly reduced CSF neurogranin level at year 4 (mean [SD] β = -242.43 [48.04] pg/mL; P < .001); reduced plasma GFAP level at year 1 (mean [SD] β = -0.02 [0.01] ng/mL; P = .02), year 2 (mean [SD] β = -0.03 [0.01] ng/mL; P = .002), and year 4 (mean [SD] β = -0.06 [0.02] ng/mL; P < .001); and increased CSF sTREM2 level at year 2 (mean [SD] β = 1.12 [0.43] ng/mL; P = .01) and year 4 (mean [SD] β = 1.06 [0.52] ng/mL; P = .04). Solanezumab significantly increased CSF NfL (log) at year 4 (mean [SD] β = 0.14 [0.06]; P = .02). Correlation analysis for rates of change found stronger correlations between CSF markers and fluid markers with Pittsburgh compound B positron emission tomography for solanezumab and placebo. CONCLUSIONS AND RELEVANCE: This randomized clinical trial supports the importance of fibrillar amyloid reduction in multiple AD-related processes of neuroinflammation and neurodegeneration in CSF and plasma in DIAD. Additional studies of antiaggregated amyloid therapies in sporadic AD and DIAD are needed to determine the utility of nonamyloid biomarkers in determining disease modification. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04623242.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Wagemann O, Liu H, Wang G, et al. Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial. JAMA Neurol. 2024. PMID: 38683602. doi:10.1001/jamaneurol.2024.0991

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。